New Perspectives in Real-World Drug Safety and Effectiveness in Cancer Treatment
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 25 February 2025 | Viewed by 1700
Special Issue Editors
Interests: hospital pharmacy; oncology pharmacy; pharmacotherapy; pharmacovigilance; pharmacology; drug interactions; epidemiology; public health; diabetes mellitus; arterial hypertension; dyslipidemia
Interests: hospital pharmacy; oncology pharmacy; geriatric oncology; pharmacotherapy; pharmacovigilance; pharmacology; drug interactions; epidemiology; public health
Interests: hospital pharmacy; oncology pharmacy; geriatric oncology; pharmacotherapy; pharmacovigilance; pharmacology; drug interactions; epidemiology; public health
Interests: pharmacotherapy; pharmacovigilance; pharmacology; drug interactions; epidemiology; public health; geriatric pharmacotherapy; clinical pharmacy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are delighted to announce that the Special Issue entitled “New Perspectives in Real-World Drug Safety and Effectiveness in Cancer Treatment” is now open to receiving proposals.
Real-world data are being increasingly used to evaluate the true effectiveness and safety of innovative antineoplastic therapies such as antibody drugs and tumor-targeted therapy. This is particularly useful for assessing clinical outcomes and drug toxicity profiles in patient populations that are often excluded from randomized clinical trials, such as older patients, or patients with comorbidities, poor performance status or pre-existing autoimmune diseases in the case of immunotherapy trials.
Furthermore, antineoplastic treatments can represent a challenge in daily clinical practice, especially in critical and frail subpopulations such as the elderly, polymedicated patients or patients with complex socio-health conditions such as those caused by the recent COVID-19 pandemic.
Some antineoplastic drugs (e.g., palbociclib for male breast cancer and pembrolizumab for tumors with microsatellite instability) have received Food and Drug Administration (FDA) approvals partially based on real-life data. Therefore, real-world evidence extracted from electronic health records, registers and patient-generated sources promises to provide clinically useful information with reduced time, cost and human effort.
This Special Issue is dedicated to reviews and original articles addressing the issues surrounding the safety and effectiveness of newly introduced cancer drugs/antineoplastic protocols, including drug safety evaluations in real-world settings, clinical consequences on patients' health/cancer treatment and drug adherence.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Real-world studies on cancer treatment;
- Real-world pharmacovigilance studies on cancer treatment;
- Real-world effectiveness studies on cancer treatment;
- Real-world outcome studies on cancer treatment;
- Real-world studies on cancer treatment with targeted therapies;
- Real-world studies on cancer treatment with immunotherapy;
- Real-world drug adherence studies on cancer treatment;
- Real-world studies on elderly patients’ cancer treatment;
- Real-world studies on cancer treatment in polymedicated patients;
- Real world studies on cancer treatment in patients with comorbidities.
We look forward to receiving your contributions.
Prof. Dr. Manuel Morgado
Dr. Patrícia Cavaco
Prof. Dr. Fátima Falcão
Prof. Dr. Fátima Roque
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- real-world evidence
- drug safety
- pharmacovigilance
- effectiveness
- targeted therapies
- immunotherapy
- oncology
- geriatric oncology
- drug adherence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
